Biomerica Receives Approval to Market Its H. Pylori and PTH Products in Mexico and Appoints New Distributor in Mexico
August 07 2013 - 8:19AM
Marketwired
Biomerica, Inc. (OTCBB: BMRA) announced today that it has received
approval to market and sell its H. Pylori and Parathyroid Hormone
(PTH) diagnostic tests in Mexico. The company also announced that
it has appointed a new distributor in Mexico with over 35 years of
experience and 200 employees overall.
Helicobacter pylori (H. pylori) is a bacterium responsible for
over 85% of ulcers. It is estimated that the worldwide anti-ulcer
market is over $9.5 billion. Epidemiological studies have shown
that the H. pylori infection is widespread, affecting over one
billion people worldwide. The disease affects both men and women
and nearly all duodenal ulcer patients and over 80% of stomach
ulcer patients are infected with the bacterium. In addition to
peptic ulcer disease, H. pylori infection has also been shown to be
a significant risk factor for stomach cancer. Biomerica's H. pylori
test allows laboratories to automate the testing for H. pylori in a
quick and cost effective manner.
Parathyroid hormone (PTH) controls calcium, phosphorus, and
vitamin D levels in the blood and bone. Release of PTH is
controlled by the level of calcium in the blood. Low blood calcium
levels cause increased PTH to be released, while high blood calcium
levels block PTH release. PTH tests are usually ordered when
someone has symptoms associated with hypercalcemia or hypocalcemia,
such as: Fatigue, Nausea, Abdominal pain and Thirst Muscle cramps.
A doctor may also order a PTH when a person has a chronic condition
such as kidney disease. Using Biomerica's PTH test, laboratories
can automate the testing for PTH in a rapid and cost effective
manner.
"We are excited about these regulatory approvals and the
addition of our new Mexico distributor," said Zackary Irani, CEO,
Biomerica. "With a potential market of over 3,500 clinical labs,
these approvals will allow our new distributor to sell and market
our product throughout the country."
Biomerica is also seeking approval for several of its other
products in Mexico.
About Biomerica (OTCBB: BMRA) Biomerica,
Inc. (www.biomerica.com) is a global biomedical company that
develops, manufactures and markets advanced diagnostic products
used at the point-of-care (in home and in physicians' offices) and
in hospital/clinical laboratories for the early detection of
medical conditions and diseases. The Company's products are
designed to enhance the health and well being of people, while
reducing total healthcare costs. Biomerica primarily focuses is on
products for Diabetes, Gastrointestinal Disease and esoteric
testing.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking; such as
statements relating to intended launch dates, sales potential,
significant benefits, market size, growth of business, favorable
positions, expansion, expected orders, leading market positions,
anticipated future revenues or production volume of the Company,
success of product and new product offerings. Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future, and
accordingly, such results may differ materially from those
expressed in any forward-looking statements made by or on behalf of
Biomerica. The potential risks and uncertainties include, among
others, fluctuations in the Company's operating results due to its
business model and expansion plans, downturns in international and
or national economies, the Company's ability to raise additional
capital, the competitive environment in which the Company will be
competing, and the Company's dependence on strategic relationships.
The Company is under no obligation to update any forward-looking
statements after the date of this release.
Contact: Zackary Irani Tel: 949-645-2111
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2024 to May 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From May 2023 to May 2024